Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | PRSS12 | P56730 | 11/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15292841 | 0.93 | MAPT (0.85) | MAPTPRSS12TP53RXFP1SMN1; SMN2 | |
| SCHEMBL10245198 | 0.80 | PRSS12 (0.72) | MAPTPRSS12F10 | |
| SCHEMBL2720970 | 0.78 | MAPT (0.85) | MAPTPRSS12TP53RXFP1SMN1; SMN2 | |
| SCHEMBL15295615 | 0.78 | PRSS12 (0.61) | MAPTPRSS12F10 | |
| SCHEMBL15283224 | 0.77 | MAPT (0.60) | MAPTPRSS12TP53RXFP1SMN1; SMN2 | |
| SCHEMBL5539863 | 0.77 | MAPT (0.60) | MAPTPRSS12TP53RXFP1SMN1; SMN2 | |
| SCHEMBL2721562 | 0.77 | PRSS12 (0.70) | PRSS12F10 | |
| SCHEMBL2721559 | 0.77 | PRSS12 (0.73) | PRSS12F10 | |
| SCHEMBL10245037 | 0.77 | MAPT (0.83) | MAPTPRSS12TP53RXFP1SMN1; SMN2 | |
| SCHEMBL2724093 | 0.77 | F10 (0.64) | PRSS12F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| EP-2635559-A2 | NEUROTRYPSIN INHIBITORS | Neurotune AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MAPT 1060/4885PRSS12 5/4885TP53 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.